Kexing Biopharm Co.,Ltd. (688136.SH) announced a shareholder inquiry transfer plan. The participating shareholder in this pre-IPO inquiry-based share transfer is Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. The transferring party plans to sell a total of 10.0628 million shares, representing 5.00% of the company's total share capital.